These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Therapeutic monitoring of cyclosporine A]. Komzáková I; Safarcík K; Brozmanová H; Grundmann M Ceska Slov Farm; 2002 Jul; 51(4):159-67. PubMed ID: 12183901 [TBL] [Abstract][Full Text] [Related]
4. Liposomal formulations of Cyclosporin A: a biophysical approach to pharmacokinetics and pharmacodynamics. Fahr A; Seelig J Crit Rev Ther Drug Carrier Syst; 2001; 18(2):141-72. PubMed ID: 11325030 [TBL] [Abstract][Full Text] [Related]
5. [What significance has the C(2) value in the treatment with cyclosporin A?]. Pham VV; Stichtenoth DO; Frölich JC Dtsch Med Wochenschr; 2004 Mar; 129(13):706. PubMed ID: 15026970 [No Abstract] [Full Text] [Related]
6. [Therapeutic monitoring by blood concentrations with the focus on cyclosporin A]. Jensen SA; Dalhoff KP Ugeskr Laeger; 2001 Apr; 163(14):2009-12. PubMed ID: 11307363 [TBL] [Abstract][Full Text] [Related]
7. Role of postdose cyclosporine monitoring in living renal transplant recipients. Thomas R; Minz M; Singh B; Heer M; Kashyap R Transplant Proc; 2004 Sep; 36(7):2104. PubMed ID: 15518761 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of cyclosporine. Midtvedt K Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380 [TBL] [Abstract][Full Text] [Related]
9. [Cyclosporin A (Sandimmun)]. Mahieu P Rev Med Liege; 1996 Jan; 51(1):107-10. PubMed ID: 8701119 [No Abstract] [Full Text] [Related]
10. Switching between cyclosporin formulations. What are the risks? Olyaei AJ; deMattos AM; Bennett WM Drug Saf; 1997 Jun; 16(6):366-73. PubMed ID: 9241491 [TBL] [Abstract][Full Text] [Related]
11. [Indications for therapeutic activity of cyclosporine]. Mourani C; Mallat S; Hachem C J Med Liban; 2003; 51(2):80-91. PubMed ID: 15298162 [TBL] [Abstract][Full Text] [Related]
12. A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue. Ozbay A; Karamperis N; Jørgensen KA Curr Clin Pharmacol; 2007 Sep; 2(3):244-8. PubMed ID: 18690871 [TBL] [Abstract][Full Text] [Related]
16. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172 [TBL] [Abstract][Full Text] [Related]
17. [The anti-calcineurins (cyclosporin and tacrolimus)]. Raymond S; Limat S; Woronoff-Lemsi MC Soins; 2007 Jun; (716):61-3. PubMed ID: 17718044 [No Abstract] [Full Text] [Related]
18. Evolution of the therapeutic drug monitoring of cyclosporine. Citterio F Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378 [TBL] [Abstract][Full Text] [Related]
19. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation]. Blanchet B Ann Pharm Fr; 2008 Mar; 66(2):96-101. PubMed ID: 18570908 [TBL] [Abstract][Full Text] [Related]
20. [Cyclosporine]. Paul C; Garat H Ann Dermatol Venereol; 2011 Dec; 138(12):836-8. PubMed ID: 22137622 [No Abstract] [Full Text] [Related] [Next] [New Search]